1. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707–714.

2. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8–15.

3. Castelli WP. Cholesterol and lipids in the risk of coronary heart disease–the Framingham Heart Study. Can J Cardiol 1988; 4(Suppl A):5A–10A.

4. Abbott RD, Wilson PW, Kannel WB et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis 1988; 8:207–211.

5. Stampfer MJ, Sacks FM, Salvini S et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325:373–381.

6. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70:733–737.

7. Bolibar I, von Eckardstein A, Assmann G et al. Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb Haemost 2000; 84:955–960.

8. Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700–1707.

9. Salonen R, Seppanen K, Rauramaa I et al. Prevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland. Arteriosclerosis 1988; 8:788–792.

10. Miller M, Seidler A, Kwiterovich PO et al. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol. Circulation 1992; 86:1165–1170.

11. Shah PK, Amin J. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 1992; 85:1279–1285.

12. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation 1994; 90:2267–2279.

13. Roth A, Eshchar Y, Keren G et al. Serum lipids and restenosis after successful percutaneous transluminal coronary angioplasty. Ichilov Magnesium Study Group. Am J Cardiol 1994; 73:1154–1158.

14. Dzavik V, Teo KK, Yokoyama S et al. Effect of serum lipid concentrations on restenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160 to 240 mg/dl and triglycerides < 350 mg/dl. Am J Cardiol 1995; 75:936–938.

15. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237–1245.

16. Rubins HB, Robins SJ, Collins D. The Veteran Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol 1996; 78:572–575.

17. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410–418.

18. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615–1622.

19. DAIS Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905–910.

20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7–22.

21. 4S Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383–1389.

22. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349–1357.

23. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335:1001–1009.

24. WOSCOPS Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440–1445.

25. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149–1158.

26. Serruys PW, De Feyter PJ, Benghozi R et al. The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int J Cardiovasc Intervent 2001; 4:165–172.

27. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90:139–143.

28. Zhao XQ, Morse JS, Dowdy AA et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study). Am J Cardiol 2004; 93:307–312.

29. Assmann G. Lipid Metabolism and Atherosclerosis. New York: Schattauer; 1982.

30. von Eckardstein A, Huang Y, Assmann G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 1994; 5:404–416.

31. Skinner ER. High-density lipoprotein subclasses. Curr Opin Lipidol 1994; 5:241–247.

32. Anantharamaiah GM, Brouillette CG, Engler JA et al. Role of amphipathic helixes in HDL structure/function. Adv Exp Med Biol 1991; 285:131–140.

33. Brouillette CG, Anantharamaiah GM. Structural models of human apolipoprotein A-I. Biochim Biophys Acta 1995; 1256:103–129.

34. Brouillette CG, Anantharamaiah GM, Engler JA et al. Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta 2001; 1531:4–46.

35. Frank PG, Marcel YL. Apolipoprotein A-I: structure-function relationships. J Lipid Res 2000; 41:853–872.

36. Segrest JP, Li L, Anantharamaiah GM et al. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 2000; 11:105–115.

37. Klon AE, Segrest JP, Harvey SC. Comparative models for human apolipoprotein A-I bound to lipid in discoidal high-density lipoprotein particles. Biochemistry 2002; 41:10895–10905.

38. Navab M, Hama SY, Hough GP et al. High density associated enzymes: their role in vascular biology. Curr Opin Lipidol 1998; 9:449–456.

39. Peelman F, Vandekerckhove J, Rosseneu M. Structure and function of lecithin cholesterol acyl transferase: new insights from structural predictions and animal models. Curr Opin Lipidol 2000; 11:155–160.

40. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000; 1529:245–256.

41. Jin W, Marchadier D, Rader DJ. Lipases and HDL metabolism. Trends Endocrinol Metab 2002; 13:174–178.

42. Tall AR. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J Intern Med 1995; 237:5–12.

43. Morton RE. Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr Opin Lipidol 1999; 10:321–327.

44. Barter PJ, Brewer HB Jr, Chapman MJ et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:160–167.

45. Tall AR, Lalanne F. Phospholipid transfer protein and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:1484–1485.

46. Huuskonen J, Olkkonen VM, Jauhiainen M et al. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001; 155:269–281.

47. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002; 13:135–139.

48. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:473–480.

49. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002; 3:49–55.

50. Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 2002; 13:357–362.

51. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 2004; 15:261–267.

52. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15:2073–2084.

53. Tselepis AD, Chapman JM. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A₂, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002; 3:57–68.

54. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol 2004; 24:216–229.

55. Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. Curr Atheroscler Rep 1999; 1:156–164.

56. Niessen HW, Krijnen PA, Visser CA et al. Type II secretory phospholipase A₂ in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res 2003; 60:68–77.

57. Hannuksela ML, Liinamaa MJ, Kesaniemi YA et al. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 1994; 110:35–44.

58. Lagrost L, Athias A, Herbeth B et al. Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. J Biol Chem 1996; 271:19058–19065.

59. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33:1051–1069.

60. Colhoun HM, Scheek LM, Rubens MB et al. Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 2001; 50:652–659.

61. Riemens SC, van Tol A, Sluiter WJ et al. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 1998; 41:929–934.

62. Kahri J, Vuorinen-Markkola H, Tilly-Kiesi M et al. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity. Atherosclerosis 1993; 102:79–89.

63. Colvin PL, Parks JS. Metabolism of high density lipoprotein subfractions. Curr Opin Lipidol 1999; 10:309–314.

64. Leroy A, Dallongeville J, Fruchart JC. Apolipoprotein A-I-containing lipoproteins and atherosclerosis. Curr Opin Lipidol 1995; 6:281–285.

65. Forte TM, McCall MR. The role of apolipoprotein A-I-containing lipoproteins in atherosclerosis. Curr Opin Lipidol 1994; 5:354–364.

66. Duverger N, Rader D, Duchateau P et al. Biochemical characterization of the three major subclasses of lipoprotein A-I preparatively isolated from human plasma. Biochemistry 1993; 32:12372–12379.

67. von Eckardstein A, Nofer JR, Assmann G. Acceleration of reverse cholesterol transport. Curr Opin Cardiol 2000; 15:348–354.

68. Barrans A, Jaspard B, Barbaras R et al. Pre-beta HDL: structure and metabolism. Biochim Biophys Acta 1996; 1300:73–85.

69. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988; 27:25–29.

70. Asztalos BF, Sloop CH, Wong L et al. Comparison of apo A-I-containing subpopulations of dog plasma and prenodal peripheral lymph: evidence for alteration in subpopulations in the interstitial space. Biochim Biophys Acta 1993; 1169:301–304.

71. Asztalos BF, Sloop CH, Wong L et al. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1993; 1169:291–300.

72. Nanjee MN, Cooke CJ, Olszewski WL et al. Concentrations of electrophoretic and size subclasses of apolipoprotein A-I-containing particles in human peripheral lymph. Arterioscler Thromb Vasc Biol 2000; 20:2148–2155.

73. Tailleux A, Bouly M, Luc G et al. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20:2453–2458.

74. Ikewaki K, Zech LA, Brewer HB Jr et al. ApoA-II kinetics in humans using endogenous labelling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. J Lipid Res 1996; 37:399–407.

75. Ikewaki K, Zech LA, Kindt M et al. Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. Arterioscler Thromb Vasc Biol 1995; 15:306–312.

76. Labeur C, Lambert G, Van Cauteren T et al. Displacement of apo A-I from HDL by apo A-II or its C-terminal helix promotes the formation of pre-beta1 migrating particles and decreases LCAT activation. Atherosclerosis 1998; 139:351–362.

77. Hime NJ, Barter PJ, Rye KA. The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J Biol Chem 1998; 273:27191–27198.

78. Lagrost L, Persegol L, Lallemant C et al. Influence of apolipoprotein composition of high density lipoprotein particles on cholesteryl ester transfer protein activity. Particles containing various proportions of apolipoproteins AI and AII. J Biol Chem 1994; 269:3189–3197.

79. Boisfer E, Lambert G, Atger V et al. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J Biol Chem 1999; 274:11564–11572.

80. McCall MR, Nichols AV, Blanche PJ et al. Lecithin:cholesterol acyltransferase-induced transformation of HepG2 lipoproteins. J Lipid Res 1989; 30:1579–1589.

81. Yamazaki S, Mitsunaga T, Furukawa T et al. Interaction of lecithin-cholesterol acyltransferase with human plasma lipoproteins and with lecithin-cholesterol vesicles. J Biol Chem 1983; 258:5847–5853.

82. Nazih H, Nazih-Sanderson F, Krempf M et al. Butyrate stimulates ApoA-IV-containing lipoprotein secretion in differentiated Caco-2 cells: role in cholesterol efflux. J Cell Biochem 2001; 83:230–238.

83. Danielsen EM, Hansen GH, Poulsen MD. Apical secretion of apolipoproteins from enterocytes. J Cell Biol 1993; 120:1347–1356.

84. Castle CK, Page ME, Marotti KR et al. Secretion of pre-beta-migrating apoA-I by cynomolgus monkey hepatocytes in culture. J Lipid Res 1991; 32:439–447.

85. Thrift RN, Forte TM, Cahoon BE et al. Characterization of lipoproteins produced by the human liver cell line, Hep G2, under defined conditions. J Lipid Res 1986; 27:236–250.

86. Barrans A, Collet X, Barbaras R et al. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem 1994; 269:11572–11577.

87. Francone OL, Royer L, Haghpassand M. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res 1996; 37:1268–1277.

88. von Eckardstein A, Jauhiainen M, Huang Y et al. Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre beta 1-HDL. Biochim Biophys Acta 1996; 1301:255–262.

89. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984; 25:1017–1058.

90. Denis M, Haidar B, Marcil M et al. Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem 2004; 279:7384–7394.

91. Favari E, Lee M, Calabresi L et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 2004; 279:9930–9936.

92. Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem 1991; 266:3080–3086.

93. Huang Y, von Eckardstein A, Wu S et al. A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci USA 1994; 91:1834–1838.

94. Asztalos B, Zhang W, Roheim PS et al. Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-alpha-migrating high-density lipoprotein particles. Arterioscler Thromb Vasc Biol 1997; 17:1630–1636.

95. Forte TM, Bielicki JK, Knoff L et al. Structural relationships between nascent apoA-I-containing particles that are extracellularly assembled in cell culture. J Lipid Res 1996; 37:1076–1085.

96. von Eckardstein A, Huang Y, Wu S et al. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler Thromb Vasc Biol 1995; 15:1755–1763.

97. Musliner TA, Long MD, Forte TM et al. Dissociation of high density lipoprotein precursors from apolipoprotein B-containing lipoproteins in the presence of unesterified fatty acids and a source of apolipoprotein A-I. J Lipid Res 1991; 32:917–933.

98. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996; 37:2473–2491.

99. Lambert G, Decout A, Vanloo B et al. The C-terminal helix of human apolipoprotein AII promotes the fusion of unilamellar liposomes and displaces apolipoprotein AI from high-density lipoproteins. Eur J Biochem 1998; 253:328–338.

100. Clay MA, Pyle DH, Rye KA et al. Formation of spherical, reconstituted high density lipoproteins containing both apolipoproteins A-I and A-II is mediated by lecithin:cholesterol acyltransferase. J Biol Chem 2000; 375:9019–9025.

101. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 145:227–238.

102. Barter PJ. Hugh Sinclair Lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler Suppl 2002; 3:39–47.

103. Trigatti B, Rigotti A, Krieger M. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr Opin Lipidol 2000; 11:123–131.

104. Krieger M. Charting the fate of the 'good cholesterol': identification and characterization of the high-density lipoprotein receptor SR-B1. Annu Rev Biochem 1999; 68:523–558.

105. Acton S, Rigotti A, Landschulz KT et al. Identification of scavenger receptor AR-BI as a high density lipoprotein receptor. Science 1996; 271:518–520.

106. Landschulz KT, Pathak RK, Rigotti A et al. Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996; 98:984–995.

107. Hirano K, Yamashita S, Nakagawa Y et al. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 1999; 85:108–116.

108. Yeh YC, Hwang GY, Liu IP et al. Identification and expression of scavenger receptor SR-BI in endothelial cells and smooth muscle cells of rat aorta in vitro and in vivo. Atherosclerosis 2002; 161:95–103.

109. Babitt J, Trigatti B, Rigotti A et al. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is a N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 1997; 272:13242–13249.

110. Silver DL, Wang N, Xiao X et al. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type I results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J Biol Chem 2001; 276:25287–25293.

111. Rhainds D, Bourgeois P, Bourret G et al. Localization and regulation of SR-BI in membrane rafts of HepG2 cells. J Cell Sci 2004; 117:3095–3105.

112. Liadaki KN, Liu T, Xu S et al. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and apo A-I mutations on receptor binding. J Biol Chem 2000; 275:21262–21271.

113. Xu S, Laccotripe M, Huang X et al. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor that mediates selective lipid uptake. J Lipid Res 1997; 38:1289–1298.

114. Ohgami N, Nagai R, Miyazaki A et al. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 2001; 276:13348–13355.

115. Rigotti A, Acton SL, Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 1995; 270:16221–16224.

116. Acton SL, Scherer PE, Lodish HF et al. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 1994; 26 9:21003–21009.

117. Marsche G, Zimmermann R, Horiuchi S et al. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J Biol Chem 2003; 278:47562–47570.

118. Fluiter K, van der Westhuijzen DR, van Berkel TJ. In vivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells. J Biol Chem 1998; 273:8434–8438.

119. Connelly MA, Klein SM, Azhar S et al. Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake. J Biol Chem 1999; 274:41–47.

120. Rodrigueza WV, Thuahnai ST, Temel RE et al. Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells. J Biol Chem 1999; 274:20344–20350.

121. Spady DK, Kearney DM, Hobbs HH. Polyunsaturated fatty acids up-regulate hepatic scavenger receptor B1 (SR-BI) expression and HDL cholesteryl ester uptake in the hamster. J Lipid Res 1999; 40:1384–1394.

122. Azzi A, Gysin R, Kempna P et al. Regulation of gene expression by alpha-tocopherol. Biol Chem 2004; 385:585–591.

123. Cao WM, Murao K, Imachi H et al. Insulin-like growth factor-I regulation hepatic scavenger receptor class BI. Endocrinology 2004; 145:5540–5547.

124. Mardones P, Pilon A, Bouly M et al. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J Biol Chem 2003; 278:7884–7890.

125. Lambert G, Amar MJ, Guo G et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003; 278:2563–2570.

126. Malerod L, Juvet LK, Hanssen-Bauer A et al. Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. Biochem Biophys Res Commun 2002; 299:916–923.

127. Silver DL, Wang N, Vogel S. Identification of small PDZK1-associated protein, DD96/MAP17, as a regulator of PDZK1 and plasma high density lipoprotein levels. J Biol Chem 2003; 278:28528–28532.

128. Silver DL. A carboxyl-terminal PDZ-interacting domain of scavenger receptor B, type I is essential for cell surface expression in liver. J Biol Chem 2002; 277:34042–34047.

129. Kocher O, Yesilaltay A, Cirovic C et al. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor class B type I and altered lipoprotein metabolism. J Biol Chem 2003; 278:52820–52825.

130. Frank PG, Marcel YL, Connelly MA et al. Stabilization of caveolin-1 by cellular cholesterol and scavenger receptor class B type I. Biochemistry 2002; 41:11931–11940.

131. Matveev S, Uittenbogaard A, van der Westhuyzen D et al. Caveolin-1 negatively regulates SR-BI mediated selective uptake of high-density lipoprotein-derived cholesteryl ester. Eur J Biochem 2001; 268:5609–5616.

132. Lambert G, Chase MB, Dugi K et al. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. J Lipid Res 1999; 40:1294–1303.

133. Collet X, Tall AR, Serajuddin H et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res 1999; 40:1185–1193.

134. Ji Y, Jian B, Wang N et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997; 272:20982–20985.

135. Yancey PG, de la Llera-Moya M, Swarnakar S et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 2000; 275:36596–36604.

136. Thuahnai ST, Lund-Katz S, Dhanasekaran P et al. Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J Biol Chem 2004; 279:12448–12455.

137. Choi SY, Hirata K, Ishida T et al. Endothelial lipase: a new lipase on the block. J Lipid Res 2002; 43:1763–1769.

138. McCoy MG, Sun GS, Marchadier B et al. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res 2002; 43:921–929.

139. deLemos AS, Wolfe ML, Long CJ et al. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation 2002; 106:1321–1326.

140. Maugeais C, Tietge UJ, Broedl UC et al. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation 2003; 108:2121–2126.

141. Jin W, Millar JS, Broedl U et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 2003; 111:357–362.

142. Jaross W, Eckey R, Medschikowski M. Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis. Eur J Clin Invest 2002; 32:383–393.

143. Ivandic B, Castellani LW, Wang XP et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999; 19:1284–1290.

144. Tietge UJ, Maugeais C, Lund-Katz S et al. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol 2002; 22:1213–1218.

145. Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002; 3:256–266.

146. Moestrup SK, Kozyraki R. Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 2000; 11:133–140.

147. Kozyraki R, Fyfe J, Kristiansen M et al. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 1999; 5:656–661.

148. Moestrup SK, Kozyraki R, Kristiansen M et al. The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J Biol Chem 1998; 273:5235–5242.

149. Hammad SM, Stefansson S, Twal WO et al. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis. Proc Natl Acad Sci USA 1999; 96:10158–10163.

150. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000; 11:243–251.

151. Schneider WJ, Nimpf J. LDL receptor relatives at the crossroad of endocytosis and signalling. Cell Mol Life Sci 2003; 60:892–903.

152. Fidge NH. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res 1999; 40:187–201.

153. Kambouris AM, Roach PD, Calvert GD et al. Retroendocytosis of high density lipoproteins by the human hepatoma cell line, HepG2. Arteriosclerosis 1990; 10:582–590.

154. Silver DL, Wang N, Tall AR. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake. J Clin Invest 2000; 105:151–159.

155. Silver DL, Jiang XC, Tall AR. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice. Possible role of leptin in stimulation of HDL turnover. J Biol Chem 1999; 274:4140–4146.

156. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000; 86:11L–14L.

157. Young CE, Karas RH, Kuvin JT. High-density lipoprotein cholesterol and coronary heart disease. Cardiol Rev 2004; 12:107–119.

158. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol 2001; 87(Suppl 5A):2B–7B.

159. Cullen P, Assmann G. High risk strategies for atherosclerosis. Clin Chim Acta 1999; 286:31–45.

160. Voss R, Cullen P, Schulte H et al. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Münster Study (PROCAM) using neural networks. Int J Epidemiol 2002; 31:1253–1262.

161. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19(Suppl A):A2–11.

162. Cullen P, von Eckardstein A, Souris S et al. Dyslipidaemia and cardiovascular risk in diabetes. Diabetes Obes Metab 1999; 1:189–198.

163. Despres JP, Lemieux I, Dagenais GR et al. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153:263–272.

164. Assmann G, Nofer JR, Schulte H. Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am 2004; 33:377–392.

165. Barter P. Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 2004; 33:393–403.

166. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007–2011.

167. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47:403–411.

168. Jeppesen J, Hein HO, Suadicani P et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97:1029–1036.

169. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21–27.

170. Silverman DI, Ginsburg GS, Pasternak RC. High-density lipoprotein subfractions. Am J Med 1993; 94:636–645.

171. Wilson HM, Patel JC, Russell D et al. Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high density lipoprotein in coronary heart disease. Clin Chim Acta 1993; 220:175–187.

172. Johansson J, Walldius G, Carlson LA. Close correlation between high-density lipoprotein and triglycerides in normotriglyceridaemia. J Intern Med 1992; 232:43–51.

173. Johansson J, Carlson LA, Landou C et al. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991; 11:174–182.

174. Kronenberg F, Stühlinger M, Trenkwalder E et al. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 2000; 36:751–757.

175. Duriez P, Fruchart JC. High-density lipoprotein subclasses and apolipoprotein A-I. Clin Chim Acta 1999; 286:97–114.

176. Davignon J, Cohn JS, Mabile L et al. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999; 286:115–143.

177. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113:589–597.

178. Luc G, Parra HJ, Zylberberg G et al. Plasma concentrations of apolipoprotein A-I containing particles in normolipidaemic young men. Eur J Clin Invest 1991; 21:118–122.

179. Puchois P, Kandoussi A, Fievet P et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68:35–40.

180. Genest JJ Jr, Bard JM, Fruchart JC et al. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis 1991; 90:149–157.

181. Amouyel P, Isorez D, Bard JM et al. Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. Arterioscler Thromb 1993; 13:1640–1644.

182. Luc G, Bard JM, Lussier-Cacan S et al. High-density lipoprotein particles in octogenarians. Metabolism 1991; 40:1238–1243.

183. Kalopissis AD, Chambaz J. Transgenic animals with altered high-density lipoprotein composition and functions. Curr Opin Lipidol 2000; 11:149–153.

184. Von Eckardstein A, Langer C, Engel Tet al. ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages. FASEB J 2001; 15:1555–1561.

185. Rubin EM, Krauss RM, Spangler EA et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353:265–267.

186. Swanson ME, Hughes TE, Denny IS et al. High level expression of human apolipoprotein A-I in transgenic rats raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein A-I. Transgenic Res 1992; 1:142–147.

187. Benoit P, Emmanuel F, Caillaud JM et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999; 99:105–110.

188. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994; 91:9607–9611.

189. Dansky HM, Charlton SA, Barlow CB et al. Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. J Clin Invest 1999; 104:31–39.

190. Tangirala RK, Tsukamoto K, Chun SH et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100:1816–1822.

191. Liu AC, Lawn RM, Verstuyft JG et al. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J Lipid Res 1994; 35:2263–2267.

192. Li H, Reddick RL, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13:1814–1821.

193. Voyiaziakis E, Goldberg IJ, Plump AS et al. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res 1998; 39:313–321.

194. Shah PK, Yano J, Reyes O et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001; 103:3047–3050.

195. Shah PK, Nilsson J, Kaul S et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 1998; 97:780–785.

196. Duverger N, Kruth H, Emmanuel F et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996; 94:713–717.

197. Warden CH, Hedrick CC, Qiao JH et al. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993; 261:469–472.

198. Escola-Gil JC, Marzal-Casacuberta A, Julve-Gil J et al. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J Lipid Res 1998; 39:457–462.

199. Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY et al. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem 1996; 271:6720–6728.

200. Schultz JR, Verstuyft JG, Gong EL et al. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993; 365:762–764.

201. Duverger N, Tremp G, Caillaud JM et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996; 273:966–968.

202. Solajic-Bozicevic N, Stavjenic-Rukavina A, Sesto M. Lecithin-cholesterol acyltransferase activity in patients with coronary artery disease examined by coronary angiography. Clin Investig 1994; 72:951–956.

203. Solajic-Bozicevic N, Stavljenic A, Sesto M. Lecithin:cholesterol acyltransferase activity in patients with acute myocardial infarction and coronary heart disease. Artery 1991; 18:326–340.

204. Kuivenhoven JA, Pritchard H, Hill J et al. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997; 38:191–205.

205. Santamarina-Fojo S, Lambert G, Hoeg JM et al. Lecithin-cholesterolacyl transferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2000; 11:267–275.

206. Dobiasova M, Frohlich JJ. Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport. Clin Chim Acta 1999; 286:257–271.

207. Jonas A. Regulation of lecithin cholesterol acyltransferase activity. Prog Lipid Res 1998; 37:209–234.

208. Berard AM, Foger B, Remalev A et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997; 3:744–749.

209. Föger B, Chase M, Amar MJ et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 1999; 274:36912–36920.

210. Hoeg JM, Santamarina-Fojo S, Berard AM et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996; 93:11448–11453.

211. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000; 105:513–520.

212. Christison JK, Rye KA, Stocker R. Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 1995; 36:2017–2026.

213. Nagano M, Yamashita S, Hirano K et al. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 2004; 11:110–121.

214. Inazu A, Koizumi J, Mabuchi H. Cholesteryl ester transfer protein and atherosclerosis. Curr Opin Lipidol 2000; 11:389–396.

215. Yamashita S, Sakai N, Hirano K et al. Molecular genetics of plasma cholesteryl ester transfer protein. Curr Opin Lipidol 1997; 8:101–110.

216. Zhong S, Sharp DS, Grove JS et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97:2917–2923.

217. Hirano K, Yamashita S, Nakajima N et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997; 17:1053–1059.

218. Moriyama Y, Okamura T, Inazu A et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998; 27:659–667.

219. Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998; 39:1071–1078.

220. Agerholm-Larsen B, Tybiaerg-Hansen A, Schnohr P et al. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study. Circulation 2000; 102:2197–2203.

221. Ordovas JM, Cupples LA, Corella D et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000; 20:1323–1329.

222. Freeman DJ, Samani NJ, Wilson V et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 2003; 24:1833–1842.

223. Marotti KR, Castle CK, Boyle TP et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364:73–75.

224. Herrera VL, Makrides SC, Xie HX et al. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med 1999; 5:1383–1389.

225. Plump AS, Masucci-Magoulas L, Bruce C et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999; 19:1105–1110.

226. Rittershaus CW, Miller DP, Thomas LJ et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20:2106–2112.

227. Sugano M, Makino N, Sawada S et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998; 273:5033–5036.

228. Okamoto H, Yonemori F, Wakitani K et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406:203–207.

229. Zhang B, Fan P, Shimoji E et al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol 2004; 24:1910–1915.

230. De Grooth GJ, Kuivenhoven JA, Stalenhoef AFH et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105:2159–2165.

231. Clark RW, Sutfin TA, Ruggeri RB et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24:490–497.

232. Schlitt A, Bickel C, Thumma P et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23:1857–1862.

233. van Haperen R, van Tol A, van Gent T et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 2002; 277:48938–48943.

234. Cheung MC, Wolfbauer G, Kennedy H et al. Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. Biochim Biophys Acta 2001; 1537:117–124.

235. Desrumaux C, Athias A, Bessede G et al. Mass concentration of plasma phospholipid transfer protein in normolipidemic type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 1999; 19:266–275.

236. Murdoch SJ, Carr MC, Hokanson JE et al. PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J Lipid Res 2000; 41:237–244.

237. Jiang XC, Tall AR, Qin S et al. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem 2002; 277:31850–31856.

238. Jiang XC, Qin S, Qiao C et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7:847–852.

239. Yang XP, Yan D, Qiao C et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 2003; 23:1601–1607.

240. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem 1995; 64:235–257.

241. Huuskonen J, Ehnholm C. Phospholipid transfer protein in lipid metabolism. Curr Opin Lipidol 2000; 11:285–289.

242. Dugi KA, Brandauer K, Schmidt N et al. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation 2001; 104:3057–3062.

243. Dugi KA, Feuerstein IM, Hill S et al. Lipoprotein lipase correlates positively and hepatic lipase inversely with calcific atherosclerosis in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17:354–364.

244. Barth JD, Jansen H, Kromhout D et al. Progression and regression of human coronary atherosclerosis. The role of lipoproteins, lipases and thyroid hormones in coronary lesion growth. Atherosclerosis 1987; 68:51–58.

245. Connelly PW, Hegele RA. Hepatic lipase deficiency. Crit Rev Clin Lab Sci 1998; 35:547–572.

246. Hokanson JE, Cheng S, Snell-Bergeon JK et al. A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increase in coronary calcification in type 1 diabetes. Diabetes 2002; 51:1208–1213.

247. Shohet RV, Vega GL, Anwar A et al. Hepatic lipase (LIPIC) promoter polymorphism in men with coronary artery disease. Allele frequency and effects on hepatic lipase activity and plasma HDL-C concentrations. Arterioscler Thromb Vasc Biol 1999; 19:1975–1978.

248. Jansen H, Verhoeven AJ, Weeks L et al. Common C-to-T substitution at position–480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol 1997; 17:2837–2842.

249. Mezdour H, Jones R, Dengremont C et al. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem 1997; 272:13570–13575.

250. Busch SJ, Barnhart RL, Martin GA et al. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994; 269:16376–16382.

251. Deeb SS, Zambon A, Carr MC et al. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res 2003; 44:1279–1286.

252. Thuren T. Hepatic lipase and HDL metabolism. Curr Opin Lipidol 2000; 11:277–283.

253. Schiering A, Menschikowski M, Mueller E et al. Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis. Atherosclerosis 1999; 144:73–78.

254. Elinder LS, Dumitrescu A, Larsson P et al. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 1997; 17:2257–2263.

255. Liu PY, Li YH, Tsai WC et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003; 24:1824–1832.

256. Kugiyama K, Ota Y, Sugiyama S et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000; 86:718–722.

257. Murakami M, Kudo I. New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr Opin Lipidol 2003; 14:431–436.

258. Kozarsky KF, Donahee MH, Glick JM et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000; 20:721–727.

259. Ueda Y, Gong E, Royer L et al. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J Biol Chem 2000; 275:20368–20373.

260. Arai T, Wang N, Bezouevski M et al. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 1999; 274:2366–2371.

261. Huszar D, Varban ML, Rinninger F et al. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. Arterioscler Thromb Vasc Biol 2000; 20:1068–1073.

262. Braun A, Trigatti BL, Post MJ et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002; 90:270–276.

263. Zhang W, Yancey PG, Su YR et al. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 2003; 108:2258–2263.

264. Hsu LA, Ko YL, Wu S et al. Association between a novel 11-base pair deletion mutation in the promoter region of the scavenger receptor class B type I gene and plasma HDL cholesterol levels in Taiwanese Chinese. Arterioscler Thromb Vasc Biol 2003; 23:1869–1874.

265. Liscum L, Munn NJ. Intracellular cholesterol transport. Biochim Biophys Acta 1999; 1438:19–37.

266. Fielding CJ, Fielding PE. Intracellular cholesterol transport. J Lipid Res 1997; 38:1503–1521.

267. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34:1637–1659.

268. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 1968; 9:155–167.

269. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21:13–27.

270. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 2003; 92:42J–49J.

271. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 2002; 161:245–254.

272. Maxfield FR, Wustner D. Intracellular cholesterol transport. J Clin Invest 2002; 110:891–898.

273. Soccio RE, Breslow JL. Intracellular cholesterol transport. Arterioscler Thromb Vasc Biol 2004; 24:1150–1160.

274. Yancey PG, Bortnick AE, Kellner-Weibel G et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23:712–719.

275. Rothblat GH, de la Llera-Moya M, Atger V et al. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 1999; 40:781–796.

276. Fielding CJ, Fielding PE. Cellular cholesterol efflux. Biochim Biophys Acta 2001; 1533:175–189.

277. Yokoyama S. Release of cellular cholesterol: molecular mechanism for cholesterol homeostasis in cells and in the body. Biochim Biophys Acta 2000; 1529:231–244.

278. Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 2004; 61:682–699.

279. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71:537–592.

280. Dean M, Hamon Y, Chimini G et al. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42:1007–1017.

281. Hamon Y, Broccardo C, Chambenoit O et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol 2000; 2:399–406.

282. Hamon Y, Luciani MF, Becq F et al. Interleukin-1beta secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1. Blood 1997; 90:2911–2915.

283. Fitzgerald ML, Morris AL, Chroni A et al. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. J Lipid Res 2004; 45:287–294.

284. Fitzgerald ML, Morris AL, Rhee JS et al. Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 2002; 277:33178–33187.

285. Chroni A, Liu T, Fitzgerald ML et al. Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1. Biochemistry 2004; 43:2126–2139.

286. Drobnik W, Borsukova H, Bottcher A et al. Apo AI/ANCA1-dependent and HDL3-mediated lipid efflux from compositionally distinct cholesterol-based microdomains. Traffic 2002; 3:268–278.

287. Marguet D, Chimini G. The ABCA1 transporter and ApoA-I: obligate or facultative partners? Trends Cardiovasc Med 2002; 12:294–298.

288. Mendez AJ, Lin G, Wade DP et al. Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway. J Biol Chem 2001; 276:3158–3166.

289. Chambenoit O, Hamon Y, Marguet D et al. Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter. J Biol Chem 2001; 276:9955–9960.

290. Wang N, Silver DL, Thiele C et al. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 2001; 276:23742–23747.

291. Tang C, Vaughan AM, Oram JF. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem 2004; 279:7622–7628.

292. Yamauchi Y, Hayashi M, Abe-Dohmae S et al. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem 2003; 278:47890–47897.

293. Haidar B, Denis M, Krimbou L et al. cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts. J Lipid Res 2002; 43:2087–2094.

294. Wang N, Silver DL, Costet P et al. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 2000; 275:33053–33058.

295. Munehira Y, Ohnishi T, Kawamoto S et al. Alpha1-syntrophin modulates turnover of ABCA1. J Biol Chem 2004; 279:15901–15095.

296. Neufeld EB, Stonik JA, Demosky SJ Jr et al. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J Biol Chem 2004; 279:15571–15578.

297. Neufeld EB, Remaley AT, Demosky SJ et al. Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem 2001; 276:27584–27590.

298. Tsukamoto K, Hirano K, Tsujii K et al. ATP-binding cassette transporter-1 induces rearrangement of actin cytoskeletons possibly through Cdc42/N-WASP. Biochem Biophys Res Commun 2001; 287:757–765.

299. Zhou X, Engel T, Goepfert C et al. The ATP binding cassette transporter A1 contributes to the secretion of interleukin 1beta from macrophages but not from monocytes. Biochem Biophys Res Commun 2002; 291:598–604.

300. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003; 17:985–993.

301. Costet P, Lalanne F, Gerbod-Giannone MC et al. Retinoic acid receptor-mediated induction of ABCA1 in macrophages. Mol Cell Biol 2003; 23:7756–7766.

302. Laffitte BA, Repa JJ, Joseph SB et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001; 98:507–512.

303. Venkateswaran A, Laffitte BA, Joseph SB et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000; 97:12097–12102.

304. Wang Y, Oram JF. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem 2002; 277:5692–5697.

305. Uehara Y, Engel T, Li Z et al. Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes 2002; 51:2922–2928.

306. Castrillo A, Joseph SB, Vaidya SA et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonisms of cholesterol metabolism. Mol Cell 2003; 12:805–816.

307. Baranova I, Vishnyakova T, Bocharov A et al. Lipopolysaccharide down regulates both scavenger receptor BI and ATP binding cassette transporter AI in RAW cells. Infect Immun 2002; 70:2995–3003.

308. Wang XQ, Panousis CG, Alfaro ML et al. Interferon-gamma-mediated downregulation of cholesterol efflux and ABC1 expression is by the Stat1 pathway. Arterioscler Thromb Vasc Biol 2002; 22:e5–9.

309. Witting SR, Maiorano JN, Davidson WS. Ceramide enhances cholesterol efflux to apolipoprotein A-I by increasing the cell surface presence of ATP-binding cassette transporter A1. J Biol Chem 2003; 278:40121–40127.

310. Wang N, Chen W, Linsel-Nitschke P et al. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 2003; 111:99–107.

311. Martinez LO, Agerholm-Larsen B, Wang N et al. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem 2003; 278:37368–37374.

312. Abe-Dohmae S, Ikeda Y, Matsuo M et al. Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein. J Biol Chem 2004; 279:604–611.

313. Wang N, Lan D, Gerbod-Giannone M et al. ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux. J Biol Chem 2003; 278:42906–42912.

314. Wang N, Lan D, Chen W et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101:9774–9779.

315. Aiello RJ, Brees D, Bourassa PA et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 2002; 22:630–637.

316. McNeish J, Aiello RJ, Guyot D et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA 2000; 97:4245–4250.

317. van Eck M, Bos IS, Kaminski WE et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci USA 2002; 99:6298–6303.

318. Haghpassand M, Bourassa PA, Francone OL et al. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest 2001; 108:1315–1320.

319. Wellington CL, Brunham LR, Zhou S et al. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. J Lipid Res 2003; 44:1470–1480.

320. Vaisman BL, Lambert G, Amar M et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 2001; 108:303–309.

321. Joyce CW, Amar MJ, Lambert G et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA 2002; 99:407–412.

322. Joseph SB, McKikkigin E, Pei L et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99:7604–7609.

323. Tangirala RK, Bischoff ED, Joseph SB et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 2002; 99:11896–11901.

324. Kuivenhoven JA, Hovingh GK, van Tol A et al. Heterozygosity for ABCA1 gene mutations: effects on enzymes, apolipoproteins and lipoprotein particle size. Atherosclerosis 2003; 171:311–319.

325. Singaraja RR, Brunham LR, Visscher H et al. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol 2003; 23:1322–1332.

326. van Dam MJ, de Groot E, Clee SM et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002; 359:37–42.

327. Clee SM, Kastelein JJ, van Dam M et al. Age and residual cholesterol efflux levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 2000; 106:1263–1270.

328. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995; 267:1034–1037.

329. Boisvert WA, Spangenberg J, Curtiss LK. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest 1995; 96:1118–1124

330. Bellosta S, Mahley RW, Sanan DA et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 1995; 96:2170–2179.

331. Fazio S, Babaev VR, Murray AB et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA 1997; 94:4647–4652.

332. Fazio S, Linton MF, Swift LL. The cell biology and physiologic relevance of ApoE recycling. Trends Cardiovasc Med 2000; 10:23–30.

333. Swertfeger DK, Bu G, Hui DY. Low density lipoprotein receptor-related protein mediates apolipoprotein E inhibition of smooth muscle cell migration. J Biol Chem 2002; 277:4141–4146.

334. Ishigami M, Swertfeger DK, Hui MS et al. Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not inhibition of migration is mediated through activation of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2000; 20:1020–1026.

335. Stannard AK, Riddell DR, Sacre SM et al. Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Biol Chem 2001; 276:46011–46016.

336. Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. J Biol Chem 1997; 272:89–95.

337. Mazzone T. Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipidol 1996; 7:303–307.

338. Fournier N, Atger V, Paul JL et al. Human ApoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum. Arterioscler Thromb Vasc Biol 2000; 20:1283–1292.

339. Steinmetz A, Barbaras R, Ghalim N et al. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem 1990; 265:7859–7863.

340. Duverger N, Ghalim N, Theret N et al. Lipoproteins containing apolipoprotein A-IV: composition and relation to cholesterol esterification. Biochim Biophys Acta 1994; 1211:23–28.

341. Nofer JR, Kehrel B, Fobker M et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002; 161:1–16.

342. Cockerill GW, Saklatvala J, Ridley SH et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol 1999; 19:910–917.

343. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15:1983–1992.

344. Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 2000; 26:529–537.

345. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 1999; 31:23–37.

346. Toikka JO, Ahotupa M, Viikari JS et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis 1999; 147:133–138.

347. Sattar N, Petrie JR, Jaap AJ. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998; 138:229–235.

348. Kuvin JT, Patel AR, Sidhu M et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol 2003; 92:275–279.

349. Kuvin JT, Ramet ME, Patel AR et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002; 144:165–172.

350. Lupattelli G, Marchesi S, Roscini AR et al. Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipidemia. Am J Cardiol 2002; 90:648–650.

351. Li XP, Zhao SP, Zhang XY et al. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 2000; 73:231–236.

352. Kaufmann PA, Gnecchi-Ruscone T, Schafers KP et al. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol 2000; 36:103–109.

353. Matsuda Y, Hirata K, Inoue N et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res 1993; 72:1103–1109.

354. Ota Y, Kugiyama K, Sugiyama S et al. Complexes of apoA-1 with phosphatidylcholine suppress dysregulation of arterial tone by oxidized LDL. Am J Physiol 1997; 273:H1215–1222.

355. Kuhn FE, Mohler ER, Satler LF et al. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 1991; 68:1425–1430.

356. Bisoendial RJ, Hovingh GK, Levels JH et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107:2944–2948.

357. Spieker LE, Sudano I, Hurlimann D et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105:1399–1402.

358. Yuhanna IS, Zhu Y, Cox BE et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7:853–857.

359. Mineo C, Yuhanna IS, Quon MJ et al. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinase. J Biol Chem 2003; 278:9142–9149.

360. Li XA, Titlow WB, Jackson BA et al. High density lipoprotein binding to scavenger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J Biol Chem 2002; 277:11058–11063.

361. Nofer JR, Hermingshaus G, Brodde M et al. Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease). J Biol Chem 2004; 279:34032–34037.

362. Tamagaki T, Sawada S, Imamura H et al. Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis 1996; 123:73–82.

363. Nofer JR, Levkau B, Wolinska I et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 2001; 276:34480–34485.

364. Sugano M, Tsuchida K, Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem Biophys Res Commun 2000; 272:872–876.

365. Suc I, Escargueil-Blanc I, Troly M et al. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 1997; 17:2158–2166.

366. Packman CH, Rosenfeld SI, Leddy JP. High-density lipoprotein and its apolipoproteins inhibit cytolytic activity of complement. Studies on the nature of inhibitory moiety. Biochim Biophys Acta 1985; 812:107–115.

367. Rosenfeld SI, Packman CH, Leddy JP. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins. J Clin Invest 1983; 71:795–808.

368. Pasqui AL, Bova G, Puccetti L et al. Complement activation in hypercholesterolemia. Nutr Metab Cardiovasc Dis 2000; 10:137–142.

369. Hamilton KK, Zhao J, Sims PJ. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. J Biol Chem 1993; 268:3632–3638.

370. Vakeva A, Jauhiainen M, Ehnholm C et al. High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma. Immunology 1994; 82:28–33.

371. Schmiedt W, Kinscherf R, Deigner HP et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18:1790–1795.

372. Fleisher LN, Tall AR, Witte LD et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982; 257:6653–6655.

373. Cockerill GW, Reed S. High-density lipoprotein: multipotent effects on cells of the vasculature. Int Rev Cytol 1999; 188:257–297.

374. Vinals M, Martinez-Gonzalez J, Badimon L. Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler Thromb Vasc Biol 1999; 19:2405–2411.

375. Vinals M, Martinez-Gonzalez J, Badimon JJ et al. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol 1997; 17:3481–3488.

376. Unoki H, Fan J, Watanabe T. Low-density lipoproteins modulate endothelial cells to secrete endothelin-1 in a polarized pattern: a study using a culture model system simulating arterial intima. Cell Tissue Res 1999; 295:89–99.

377. Tsai AL, Hsu MJ, Patsch W et al. Regulation of PGI₂ activity by serum proteins: serum albumin but not high density lipoprotein is the PGI₂ binding and stabilizing protein in human blood. Biochim Biophys Acta 1991; 1115:131–140.

378. Aoyama T, Yui Y, Morishita H et al. Prostaglandin I₂ half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 1990; 81:1784–1791.

379. Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90:1138–1144.

380. Navab M, Imes SS, Hama SY et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88:2039–2046.

381. Ashby DT, Rye KA, Clay MA et al. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18:1450–455.

382. Calabresi L, Franceschini G, Sirtori CR et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997; 238:61–65.

383. Cockerill GW, Rye KA, Gamble JR et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15:1987–1994.

384. Xia P, Vadas MA, Rye KA et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999; 274:33143–33147.

385. Cockerill GW, McDonald MC, Mota-Filipe H et al. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J 2001; 15:1941–1952.

386. Cockerill GW, Huehns TY, Weerasinghe A et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001; 103:108–112.

387. Theilmeier G, Dr Geest B, Van Veldhoven PP et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J 2000; 14:2032–2039.

388. Dimayuga P, Zhu J, Oguchi S et al. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun 1999; 264:465–468.

389. Meade TW, Ruddock V, Stirling Y et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076–1079.

390. Lowe GD, Yarnell JW, Sweetnam PM et al. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79:129–133.

391. Kaneko T, Wada H, Wakita Y et al. Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. Blood Coagul Fibrinolysis 1994; 5:385–392.

392. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140:271–280.

393. Carson SD. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett 1981; 132:37–40.

394. Epand RM, Stafford A, Leon B et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 1994; 14:1775–1783.

395. Griffin JH, Kojima K, Banka CL et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103:219–227.

396. Naqvi TZ, Shah PK, Ivey PA et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999; 84:1011–1017.

397. Nofer JR, Walter M, Kehrel B. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998; 18:861–869.

398. Aviram M, Brook JG. Platelet interaction with high and low density lipoproteins. Atherosclerosis 1983; 46:259–268.

399. Li D, Weng S, Yang B et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999; 19:378–383.

400. Nofer JR, Tepel M, Kehrel B et al. High density lipoproteins enhance the Na⁺/H⁺ antiport in human platelets. Thromb Haemost 1996; 75:635–641.

401. Navab M, Berliner JA, Subbanagounder G et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21:481–488.

402. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044:275–283.

403. Navab M, Hama SY, Cooke CJ. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41:1481–1494.

404. Navab M, Hama SY, Anantharamaiah GM et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41:1495–1508.

405. Hayek T, Oiknine J, Dankner G et al. HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 1995; 33:721–725.

406. Gowri MS, Van der Westhuyzen DR, Bridges SR et al. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999; 19:2226–2233.

407. Garner B, Waldeck AR, Witting PK et al. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273:6088–6095.

408. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89:10316–10320.

409. Navab M, Hama SY, Reddy ST et al. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 2002; 13:363–372.

410. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003; 14:421–430.

411. Bochoov VN, Mechtcheriakova D, Lucerna M et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood 2002; 99:199–206.

412. Subbanagounder G, Wong JW, Lee H et al. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem 2002; 277:7271–7281.

413. Subbanagounder G, Deny Y, Borromeo C et al. Hydroxy alkenal phospholipids regulate inflammatory functions of endothelial cells. Vasc Pharmacol 2002; 38:201–209.

414. Pontsler AV, St Hilaire A, Marathe GK et al. Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem 2002; 277:13029–13036.

415. Shih DM, Gu L, Hama S et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630–1639.

416. Navab M, Anantharamaiah GM, Reddy ST et al. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Curr Opin Investig Drugs 2003; 4:1100–1104.

417. Navab M, Anantharamaiah GM, Hama S et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105:290–292.

418. Hedrick CC, Hassan K, Hough GP et al. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol 2000; 20:1946–1952.

419. Shih DM, Xia YR, Wang XP et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275:17527–17535.

420. Shih DM, Gu L, Xia YR et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284–287.

421. Oda MN, Bielicki JK, Ho TT et al. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 2002; 290:921–927.

422. Tward A, Xia YR, Wang XP et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106:484–490.

423. Deakin S, Leviev I, Guernier S et al. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003; 23:2083–2089.

424. Tomas M, Senti M, Garcia-Faria F et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000; 20:2113–2119.

425. Adkins S, Gan KN, Mody M et al. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52:598–608.

426. Humbert R, Adler DA, Disteche CM et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3:73–76.

427. Bauters C, Amant C, Boullier A et al. Paraoxonase polymorphism (Gln192Arg) as a determinant of the response of human coronary arteries to serotonin. Circulation 2000; 101:740–743.

428. Sanghera DK, Saha N, Aston CE et al. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17:1067–1073.

429. Wang X, Fan Z, Huang J et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 2003; 23:328–334.

430. Jarvik GP, Hatsukami TS, Carlson C et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003; 23:1465–1471.

431. Robertson KS, Hawe E, Miller GJ et al. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Part Heart Study II. Biochim Biophys Acta 2003; 1639:203–212.

432. Quarck R, De Geest B, Stengel D et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103:2495–2500.

433. Yamada Y, Yoshida H, Ichihara S et al. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000; 150:209–216.

434. Tsimihodimos V, Karabina SA, Tambaki AP et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002; 43:256–263.

435. Lee C, Sigari F, Segrado T et al. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. Arterioscler Thromb Vasc Biol 1999; 19:1437–1446.

436. Langer C, Gansz B, Goepfert C et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 2002; 296:1051.

437. Harnish DC, Evans MJ, Scicchitano MS et al. Estrogen regulation of the apolipoprotein AI gene promoter through transcription cofactor sharing. J Biol Chem 1998; 273:9270–9278.

438. Funke H. Genetic determinants of high density lipoprotein levels. Curr Opin Lipidol 1997; 8:189–196.

439. von Eckardstein A, Assmann G. High density lipoproteins and reverse cholesterol transport: lessons from mutations. Atherosclerosis 1998; 137(Suppl):S7–S11.

440. Funke H. Familial HDL deficiency syndromes. In: Atherosclerosis XI. Edited by B Jacotot, D Mathe and JC Fruchart. Singapore: Excerpta Medica/Elsevier Science, 1997;713–731.

441. Assmann G, von Eckardstein A, Funke H. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 1993; 87(Suppl 3):III28–34.

442. Assmann G, von Eckardstein A, Brewer HB Jr. Analphalipoproteinemia: Tangier disease. In: The Metabolic and Molecular Bases of Inherited Diseases. 8th edition. Edited by CR Scriver, AL Beaudet, WS Sly and D Valle. New York: McGraw-Hill Publishing Company, 2001;2937–2960.

443. Hayden MR, Clee SM, Brooks-Wilson A et al. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol 2000; 11:117–122.